Protocol Ledger

NCT03592472 · Phase III · RECRUITING

A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma (RENAVIV)

Interventional Phase III clinical trial protocol NCT03592472 sponsored by Xynomic Pharmaceuticals in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2018-07-17 Enrollment: 413 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT03592472
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)413 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03592472
Protocol FieldVerified Registry Value
NCT IdentifierNCT03592472
Consolidated Lead SponsorXynomic Pharmaceuticals
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment413 participants (ESTIMATED)
Registered Start Date2018-07-17
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI